⚡ Quick Answer — What is Seretra?
Seretra obsahuje seratrodast 80 mg, , selective thromboxane A2 (TXA2) receptor antagonist used as preventer therapy for asthma and allergic rhinitis. Seratrodast blocks the TXA2 receptor on bronchial smooth muscle, eosinophils, and platelets — preventing TXA2-mediated bronchoconstriction, eosinophil recruitment, and airway hyperresponsiveness. It was developed and is mainly used in Japan; less widely available outside Asia. Used as add-on preventer alongside ICS in patients with persistent asthma. Onset of preventer benefit takes 1–2 weeks of daily dosing.
📦 Každá objednávka je pokryta naší Zárukou opětovného odeslání — pokud vaše zásilka nedorazí do 20 pracovních dnů, přeposíláme ji.
Proč objednávat z MedsBase
Naše generické léky pocházejí od výrobců certifikovaných WHO-GMP a jsou expedovány po celém světě v diskrétním, nenápadném balení – na vnější straně balíku není uveden název léku. Platby kartou jsou směrovány prostřednictvím regulovaného procesoru (popisky na výpisu zahrnují regulovaného procesora plateb kartou – nikdy “MedsBase” nebo název léku). Přijímáme také kryptoměny a bankovní převody SEPA. Každá objednávka je zajištěna naší politikou přeposlání.
What Is Seretra?
Seretra contains seratrodast — a niche anti-asthma agent introduced in Japan in 1995. Seratrodast targets the thromboxane A2 (TXA2) receptor — a contrast to leukotriene receptor antagonists (montelukast) which target the cysteinyl leukotriene receptor. Both TXA2 and leukotrienes are inflammatory mediators released during the allergic cascade.
How Does Seratrodast Work?
- TXA2 receptor blockade on bronchial smooth muscle prevents TXA2-mediated bronchoconstriction
- Reduces eosinophil recruitment to airways
- Decreases airway hyperresponsiveness over 1–2 weeks of dosing
- Mild platelet inhibition — TXA2 is a potent platelet aggregator; this effect is rarely clinically significant
Použití a indikace
- Persistent asthma — add-on preventer when ICS alone is inadequate
- Allergic rhinitis — adjunct
- Cough-variant asthma
- Aspirin-exacerbated respiratory disease (AERD) — niche use
Seretra Dosage
| Patient | Dávka | Frekvence |
|---|---|---|
| Adults | 80 mg | Once daily after dinner |
| Hepatic impairment | Reduce dose 50% | Once daily |
Side Effects of Seretra
- Nausea, dyspepsia
- Bolest hlavy
- Mild dizziness
- Mild liver enzyme elevation
- Rarely: rash, fatigue
Serious — stop and seek help:
- Hepatitis (jaundice, dark urine, RUQ pain)
- Severe allergic reaction
- Severe persistent vomiting
Varování a opatření
- Liver function monitoring: baseline LFTs and periodic monitoring during long-term use.
- Continue ICS if previously prescribed; seratrodast is add-on, not replacement.
- Not a rescue medication. Use SABA (Asthalin, Levolin) for acute attacks.
- Těhotenství a kojení: limited data; avoid unless benefit clear.
- Bleeding disorders: mild TXA2 inhibition could theoretically prolong bleeding; rarely clinically significant.
Kontraindikace
- Hypersensitivity to seratrodast
- Severe hepatic impairment
- Active hepatitis
Interakce s léčivy
- Aspirin and other antiplatelet agents — additive bleeding risk (rarely clinically significant)
- Warfarin — monitor INR
- Other hepatotoxic drugs — monitor LFTs
Skladování
- Store below 25°C in a cool, dry place away from direct sunlight.
- Keep in original packaging until use to protect from moisture and light.
- Do not use after the expiry date printed on the strip.
- Keep out of reach of children.
Související alternativy na MedsBase
- Asthalin Inhaler — salbutamol reliever
- Budecort Inhaler — budesonide ICS preventer
- Foracort Inhaler — budesonide + formoterol ICS-LABA
- Montair — montelukast LTRA tablet
- Tiova Inhaler — tiotropium LAMA for COPD
Často kladené dotazy
How is seratrodast different from montelukast?
Both block specific allergic mediators. Montelukast (Montair) blocks the cysteinyl leukotriene CysLT1 receptor. Seratrodast blocks the thromboxane A2 receptor. Different mediators, different targets, similar add-on niche. Montelukast has more global use and a stronger evidence base; seratrodast is mainly used in Japan and parts of Asia.
Can I take Seretra alongside montelukast?
Combination is not standard. Discuss with your prescriber — there is no established additional benefit over ICS-LABA + LTRA.
How long until Seretra works?
1–2 weeks for noticeable improvement; 4–8 weeks for full preventer effect on exacerbation rate.
Is Seretra a rescue inhaler?
No — onset is far too slow. Use a SABA (Asthalin, Levolin) for acute attacks.
Why monitor liver function?
Mild liver enzyme elevation is a known side effect. Baseline LFTs and periodic monitoring are recommended.
Will Seretra replace my inhaler?
No — seratrodast is an oral add-on. Continue ICS or ICS-LABA inhaler therapy.
Is Seretra evidence-based?
Yes, but mainly through Japanese trials. Evidence base is smaller than for montelukast or ICS-LABA combinations. Reasonable as add-on in selected patients.
Can children take Seretra?
Limited paediatric data; specialist supervision required.
Is Seretra safe in pregnancy?
Limited data; avoid unless benefit clear.
Související alternativy
Další produkty v Chronická onemocnění které zákazníci také prohlížejí:





























Hodnocení
Zatím zde nejsou žádná hodnocení